Profile data is unavailable for this security.
About the company
CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.
- Revenue in HKD (TTM)665.61m
- Net income in HKD-946.44m
- Incorporated2009
- Employees1.49k
- LocationCanSino Biologics IncWest District Biomedical Park, No. 185South Avenue, West District, EconomicTIANJIN 300457ChinaCHN
- Phone+86 2 258213766
- Fax+86 2 258213626
- Websitehttp://www.cansinotech.com/
More ▼
6.85%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 02 Oct 2024 | 3.28m | 2.47% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 1.31m | 0.99% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 896.20k | 0.68% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 893.52k | 0.67% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 621.80k | 0.47% |
| HSBC Jintrust Fund Management Co. Ltd.as of 30 Jun 2024 | 572.20k | 0.43% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 496.00k | 0.37% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 401.60k | 0.30% |
| BlackRock Advisors (UK) Ltd.as of 03 Oct 2024 | 381.60k | 0.29% |
| CSOP Asset Management Ltd.as of 03 Oct 2024 | 232.41k | 0.18% |
More ▼
Data from 30 Jun 2024 - 29 Oct 2024Source: FactSet Research Systems Inc.
